

SUPPLEMENTARY DATA


**Prostaglandin F<sub>2α</sub> facilitates hepatic glucose production through CaMKII $\gamma$ /p38/FoxO1-signaling pathway in fasting and obesity**

Yuanyang Wang<sup>1</sup>, Shuai Yan<sup>2</sup>, Bing Xiao<sup>2,3</sup>, Shengkai Zuo<sup>2</sup>, Qianqian Zhang<sup>2</sup>, Guilin Chen<sup>1</sup>, Yu Yu<sup>2,4</sup>, Di Chen<sup>2,5</sup>, Qian Liu<sup>1</sup>, Yi Liu<sup>2</sup>, Yujun Shen<sup>1,\*</sup>, Ying Yu<sup>1,2\*</sup>

<sup>1</sup>Department of Pharmacology, School of Basic Medical Sciences, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin 300070, China; <sup>2</sup>Key Laboratory of Food Safety Research, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China; <sup>3</sup>State Key Laboratory for Medical Genomics, School of Life Science and Biotechnology, Shanghai JiaoTong University, Shanghai 200240, China; <sup>4</sup>Department of Pediatric Cardiology, Xinhua Hospital affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China; <sup>5</sup>Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.


**\*To whom correspondence** may be addressed: Ying Yu, MD, PhD or Yujun Shen, PhD. Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, 22 Qixiangtai Rd, Heping District, Tianjin 300070, China. Tel and Fax: 86-22-83336627. Email: [yuying@sibs.ac.cn](mailto:yuying@sibs.ac.cn); [yuying@tmu.edu.cn](mailto:yuying@tmu.edu.cn) or [yujun\\_shen@tmu.edu.cn](mailto:yujun_shen@tmu.edu.cn)

**Supplementary Figure 1.** Hepatic glycogen content in fed or fasted mice after FP shRNA adenovirus infection ( $n = 4$ ).




SUPPLEMENTARY DATA

**Supplementary Figure 2. Characterization of hFP transgenic mice.** (A) The Cre-loxP strategy for generation of HCTG mice. (B) PCR genotyping of tail biopsies of offspring from the mating of hFP Tg-Stop with Alb<sup>Cre</sup> mice. HCTG mice expressing both hFP (465 bp) and Alb<sup>Cre</sup> (510 bp). (C) Representative liver immunofluorescence-staining images of mCherry in Tg-hFP-STOP<sup>Flox</sup> mice and HCTG mice (mCherry-negative). (D) mRNA levels of hFP in different tissues from NTG and HCTG mice. \*\**P* < 0.01 vs. NTG (*n* = 6). Ht, heart; Lv, liver; Sp, spleen; Ln, lung; Kd, kidney; Ms, muscle; Ft, fat; Bn, brain. (E) Immunoblotting assays of hFP protein in different tissues from NTG and HCTG mice.




SUPPLEMENTARY DATA

**Supplementary Figure 3. Body weight, body composition, and lipid profiles in hFP HCTG mice.** (A) Body weights and (B) body compositions of HCTG and NTG littermates (8-weeks old) ( $n = 7$ ). (C) Plasma total triglyceride and cholesterol levels in HCTG and NTG littermates (8-weeks old) after feeding or 8 h of fasting.




SUPPLEMENTARY DATA

**Supplementary Figure 4. Silencing CaMKII $\gamma$  or p38 significantly attenuates PGF $_{2\alpha}$ -induced hepatic glucose production (HGP).** (A) CaMKII $\gamma$  and p38 $\alpha$  mRNA expression levels in primary hepatocytes treated with shRNA adenovirus. \* $P < 0.01$  vs. Control ( $n = 3$ ). (B,C) Hepatic glucose production in PGF $_{2\alpha}$ -stimulated NTG and HCTG hepatocytes after infection with CaMKII $\gamma$  shRNA or P38 shRNA adenovirus, respectively. \* $P < 0.01$  vs. NTG, #  $P < 0.05$  vs. Control( $n = 3$ ). (D,E) Expression of PCK1 and G6Pase protein in NTG and HCTG hepatocytes after infection with CaMKII $\gamma$  shRNA or P38 shRNA adenovirus, respectively.




SUPPLEMENTARY DATA

**Supplementary Figure 5. Mutation of p38 phosphorylation sites in FoxO1 protein leads to nuclear translocation defect in response to PGF<sub>2α</sub> in HCTG hepatocytes.** NTG and HCTG hepatocytes were transfected with adenovirus encoding WT-FLAG-FoxO1 or 9A-FLAG-FoxO1 mutant, then stimulated with PGF<sub>2α</sub>. Nuclear and cytosolic distribution of FoxO1 were assayed by immunoblot.



**Supplementary Figure 6. Construction and characterization of hepatocyte-specific FP-deficient mice.** (A) The Cre-loxP strategy for generation of hepatocyte-specific FP-knockout mice (*FP<sup>F/F</sup> Alb<sup>cre</sup>*). (B) PCR genotyping of tail biopsies of offspring from wild-type, *FP<sup>F/F</sup>*, and *FP<sup>F/F</sup> Alb<sup>cre</sup>* mice. *FP<sup>F/F</sup> Alb<sup>cre</sup>* mice showed both bands of *FP<sup>F/F</sup>* (300 bp) and *Alb<sup>cre</sup>* (510 bp). (C) mRNA levels of FP in different tissues from *FP<sup>F/F</sup>* and *FP<sup>F/F</sup> Alb<sup>cre</sup>* mice. \*\**P* < 0.01 vs. *FP<sup>F/F</sup>* (*n* = 6). Ht, heart; Lv, liver; Sp, spleen; Ln, lung; Kd, kidney; Ms, muscle; Ft, fat; Bn, brain.



SUPPLEMENTARY DATA

**Supplementary Table S1.** Primers for PCR.

	Forward primer (5'–3')	Reverse primer (5'–3')
hFP	ACCTCCCCCTGAACCTGAAA	CGATGGCAAGGCTGTTTGAC
Alb-Cre	CCAGGCTAAGTGCCTTCTCTACA	AATGCTTCTGTCCGTTTGCCG
CaMKII $\alpha$	TGCCTGGTGTGCTAACCC	CCATTA ACTGAACGCTGGA ACT
CaMKII $\beta$	GCACGTCATTGGCGAGGAT	ACGGGTCTCTTCGGACTGG
CaMKII $\gamma$	ACCGACGACTACCAGCTTTTC	GCAGCATATTCTGCGTAGATG
CaMKII $\delta$	TCAAGGCCGGAGCTTACGA	GAGGCTGTGATACGTTTGGCA
$\beta$ -actin	AACGCAGCTCAACAGTCC	TGGAATCCTGTGGCATCCATG

**Supplementary Table S2.** Primers for real-time PCR.

	Forward primer (5'–3')	Reverse primer (5'–3')
FP	GAAGTTCAGAAGCCAGCAGCATA	AGCAACGACTGGCAAGTTTATAC
hFP	CCATTCGGAGAGCAAAAAGT	AGCTCCTGGCGATAATGTGT
G6Pase	CCATGGGCGCAGCAGGTG	AGGTAGATCCGGGACAGACAGACG
PCK1	CGCTGGATGTTCGGAAGAG	AGTCTGTCAGTTCAATACCAATC
Pygl	GCCATCGCCGTGTTGAC	GCCCTGACGGCAGCATT
P38	CTGACCGACGACCACGTTC	CTTCGTTACAGCTAGGTTGC
CaMKII $\alpha$	TGCCTGGTGTGCTAACCC	CCATTA ACTGAACGCTGGA ACT
CaMKII $\beta$	GCACGTCATTGGCGAGGAT	ACGGGTCTCTTCGGACTGG
CaMKII $\gamma$	ACCGACGACTACCAGCTTTTC	GCAGCATATTCTGCGTAGATG
CaMKII $\delta$	TCAAGGCCGGAGCTTACGA	GAGGCTGTGATACGTTTGGCA
h18S	CAGCCACCCGAGATTGAGCA	TAGTAGCGACGGGCGGTGTG
18S	AGGGGAGAGCGGGTAAGAGA	GGACAGGACTAGGCGGAACA
$\beta$ -actin	CGTGCGTGACATCAAAGAGAAG	CGTTGCCAATAGTGATGACCTG

SUPPLEMENTARY DATA

**Supplementary Table S3.** List of antibodies

Antibody	Manufacturer	Catalog Number
<b>PCK1</b>	Proteintech, China	16754-1-AP
<b>p38</b>	Proteintech, China	14064-1-AP
<b>lamin B</b>	Proteintech, China	12987-1-AP
<b>G6Pase</b>	Santa Cruz Biotechnology, USA	sc-25840
<b>CaMKII<math>\gamma</math></b>	Santa Cruz Biotechnology, USA	sc-1541
<b><math>\alpha</math>-tubulin</b>	Cell Signaling Technology, USA	2125
<b>phospho-Thr287 CaMKII<math>\gamma</math></b>	Cell Signaling Technology, USA	12716
<b>phospho-p38</b>	Cell Signaling Technology, USA	4511
<b>FoxO1</b>	Cell Signaling Technology, USA	2880
<b>HA-Tag</b>	Cell Signaling Technology, USA	5017
<b>hFP</b>	Epitomics, USA	5523-1
<b><math>\beta</math>-actin</b>	Sigma-Aldrich, USA	A5441

**Supplementary Table S4.** shRNA Sequences

shRNA	Forward (5'–3')	Reverse (5'–3')
FP	GATCCCGCCTTAAAGGTTGCTGCT ATTTGAAGCTTGAAATAGCAGCAA CCTTTAAGGTTTTTT	CTAGAAAAAACCTTAAAGGTTGCTGCT ATTTCAAGCTTCAAATAGCAGCAACCT TTAAGGCGG
CaMKII $\gamma$	GATCCCGTTAATGATTTCTTGTTTT CTCGAAGCTTGAAAACAAGAAAT CATTAAAGATTTTTT	CTAGAAAAAATTAATGATTTCTTGTTTT TCTCCAAGCTTCGAAAACAAGAAATCA TTAAGACGG
P38	GATCCCGTGACCGGAAGAACGTT GTTTCGAAGCTTGAAAACAACGTT CTTCCGGTCATTTTTT	CTAGAAAAAATGACCGGAAGAACGTT GTTTCCAAGCTTCGAAAACAACGTTCTT CCGGTCACGG